HYPR
Hyperfine, Inc.
Medical - Devices
Market Cap$158M
5Y Perf.-83.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
HYPR vs NVCR
Revenue, margins, valuation, and 5-year total return — side by side.
NVCR
NovoCure Limited
Medical - Instruments & Supplies
Market Cap$1.92B
5Y Perf.-89.5%
HYPR vs NVCR — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | HYPR | NVCR |
|---|---|---|
| Industry | Medical - Devices | Medical - Instruments & Supplies |
| Market Cap | $158M | $1.92B |
| Revenue (TTM) | $14M | $674M |
| Net Income (TTM) | $-36M | $-173M |
| Gross Margin | 49.8% | 75.2% |
| Operating Margin | -273.4% | -27.2% |
| Total Debt | $0.00 | $290M |
| Cash & Equiv. | $35M | $103M |
HYPR vs NVCR — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
HYPR
NVCR
| Stock | Jan 21 | May 26 | Return |
|---|---|---|---|
| Hyperfine, Inc. (HYPR) | 100 | 16.6 | -83.4% |
| NovoCure Limited (NVCR) | 100 | 10.5 | -89.5% |
Price return only. Dividends and distributions are not included.
Quick Verdict: HYPR vs NVCR
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: NVCR leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and profitability and margin quality. Hyperfine, Inc. is the stronger pick specifically for recent price momentum and sentiment. As sector peers, any of these can serve as alternatives in the same allocation.
HYPR
Hyperfine, Inc.
The Growth Play
HYPR is the clearest fit if your priority is growth exposure.
- Rev growth 5.2%, EPS growth 23.2%, 3Y rev CAGR 25.8%
- +137.1% vs NVCR's +1.1%
Best for: growth exposure
NVCR
NovoCure Limited
The Income Pick
NVCR carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 2.20
- 30.3% 10Y total return vs HYPR's -83.2%
- Lower volatility, beta 2.20, Low D/E 85.2%, current ratio 2.90x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | NVCR | 8.3% revenue growth vs HYPR's 5.2% |
| Quality / Margins | NVCR | -25.7% margin vs HYPR's -262.3% |
| Stability / Safety | NVCR | Beta 2.20 vs HYPR's 2.63 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | HYPR | +137.1% vs NVCR's +1.1% |
| Efficiency (ROA) | NVCR | -16.5% ROA vs HYPR's -72.8%, ROIC -16.4% vs -316.4% |
HYPR vs NVCR — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
HYPR vs NVCR — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLNVCRLAGGINGHYPR
HYPRHyperfine, Inc.
1leads
NVCRNovoCure Limited
4leads
6 Total Categories
CATEGORYLEADERvs HYPRMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
NVCR4/6
Valuation MetricsMultiples, price ratios, and targets
NVCR2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
NVCR5/7
Total Returns1Y, 3Y, 5Y total returns with dividends
HYPR5/6
Risk & VolatilityBeta, volatility, and downside exposure
NVCR2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
NVCR leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
NVCR is the larger business by revenue, generating $674M annually — 49.7x HYPR's $14M. Profitability is closely matched — net margins range from -25.7% (NVCR) to -2.6% (HYPR). On growth, HYPR holds the edge at +128.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | HYPRHyperfine, Inc. | NVCRNovoCure Limited |
|---|---|---|
| RevenueTrailing 12 months | $14M | $674M |
| EBITDAEarnings before interest/tax | -$35M | -$165M |
| Net IncomeAfter-tax profit | -$36M | -$173M |
| Free Cash FlowCash after capex | -$29M | -$48M |
| Gross MarginGross profit ÷ Revenue | +49.8% | +75.2% |
| Operating MarginEBIT ÷ Revenue | -2.7% | -27.2% |
| Net MarginNet income ÷ Revenue | -2.6% | -25.7% |
| FCF MarginFCF ÷ Revenue | -2.1% | -7.1% |
| Rev. Growth (YoY)Latest quarter vs prior year | +128.0% | +12.3% |
| EPS Growth (YoY)Latest quarter vs prior year | +56.6% | -100.0% |
NVCR leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
NVCR leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | HYPRHyperfine, Inc. | NVCRNovoCure Limited |
|---|---|---|
| Market CapShares × price | $158M | $1.9B |
| Enterprise ValueMkt cap + debt − cash | $123M | $2.1B |
| Trailing P/EPrice ÷ TTM EPS | -3.91x | -13.80x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 11.67x | 2.92x |
| Price / BookPrice ÷ Book value/share | 3.86x | 5.51x |
| Price / FCFMarket cap ÷ FCF | — | — |
NVCR leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
NVCR leads this category, winning 5 of 7 comparable metrics.
Profitability & Efficiency
NVCR delivers a -50.8% return on equity — every $100 of shareholder capital generates $-51 in annual profit, vs $-97 for HYPR. On the Piotroski fundamental quality scale (0–9), NVCR scores 5/9 vs HYPR's 3/9, reflecting solid financial health.
| Metric | HYPRHyperfine, Inc. | NVCRNovoCure Limited |
|---|---|---|
| ROE (TTM)Return on equity | -97.4% | -50.8% |
| ROA (TTM)Return on assets | -72.8% | -16.5% |
| ROICReturn on invested capital | -3.2% | -16.4% |
| ROCEReturn on capital employed | -79.2% | -28.9% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 5 |
| Debt / EquityFinancial leverage | — | 0.85x |
| Net DebtTotal debt minus cash | -$35M | $187M |
| Cash & Equiv.Liquid assets | $35M | $103M |
| Total DebtShort + long-term debt | $0 | $290M |
| Interest CoverageEBIT ÷ Interest expense | — | -96.80x |
NVCR leads this category, winning 5 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
HYPR leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in HYPR five years ago would be worth $1,688 today (with dividends reinvested), compared to $875 for NVCR. Over the past 12 months, HYPR leads with a +137.1% total return vs NVCR's +1.1%. The 3-year compound annual growth rate (CAGR) favors HYPR at 4.8% vs NVCR's -37.6% — a key indicator of consistent wealth creation.
| Metric | HYPRHyperfine, Inc. | NVCRNovoCure Limited |
|---|---|---|
| YTD ReturnYear-to-date | +73.4% | +28.3% |
| 1-Year ReturnPast 12 months | +137.1% | +1.1% |
| 3-Year ReturnCumulative with dividends | +15.1% | -75.7% |
| 5-Year ReturnCumulative with dividends | -83.1% | -91.3% |
| 10-Year ReturnCumulative with dividends | -83.2% | +30.3% |
| CAGR (3Y)Annualised 3-year return | +4.8% | -37.6% |
HYPR leads this category, winning 5 of 6 comparable metrics.
Risk & Volatility
NVCR leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
NVCR is the less volatile stock with a 2.20 beta — it tends to amplify market swings less than HYPR's 2.63 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. NVCR currently trades 83.9% from its 52-week high vs HYPR's 75.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | HYPRHyperfine, Inc. | NVCRNovoCure Limited |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.63x | 2.20x |
| 52-Week HighHighest price in past year | $2.22 | $20.06 |
| 52-Week LowLowest price in past year | $0.53 | $9.82 |
| % of 52W HighCurrent price vs 52-week peak | +75.7% | +83.9% |
| RSI (14)Momentum oscillator 0–100 | 71.7 | 69.8 |
| Avg Volume (50D)Average daily shares traded | 603K | 1.5M |
NVCR leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates HYPR as "Buy" and NVCR as "Buy". Consensus price targets imply 99.0% upside for NVCR (target: $34) vs -4.8% for HYPR (target: $2).
| Metric | HYPRHyperfine, Inc. | NVCRNovoCure Limited |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $1.60 | $33.50 |
| # AnalystsCovering analysts | 4 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
NVCR leads in 4 of 6 categories (Income & Cash Flow, Valuation Metrics). HYPR leads in 1 (Total Returns).
Best OverallNovoCure Limited (NVCR)Leads 4 of 6 categories
Loading custom metrics...
HYPR vs NVCR: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is HYPR or NVCR a better buy right now?
For growth investors, NovoCure Limited (NVCR) is the stronger pick with 8.
3% revenue growth year-over-year, versus 5. 2% for Hyperfine, Inc. (HYPR). Analysts rate Hyperfine, Inc. (HYPR) a "Buy" — based on 4 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — HYPR or NVCR?
Over the past 5 years, Hyperfine, Inc.
(HYPR) delivered a total return of -83. 1%, compared to -91. 3% for NovoCure Limited (NVCR). Over 10 years, the gap is even starker: NVCR returned +30. 3% versus HYPR's -83. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — HYPR or NVCR?
By beta (market sensitivity over 5 years), NovoCure Limited (NVCR) is the lower-risk stock at 2.
20β versus Hyperfine, Inc. 's 2. 63β — meaning HYPR is approximately 19% more volatile than NVCR relative to the S&P 500.
04Which is growing faster — HYPR or NVCR?
By revenue growth (latest reported year), NovoCure Limited (NVCR) is pulling ahead at 8.
3% versus 5. 2% for Hyperfine, Inc. (HYPR). On earnings-per-share growth, the picture is similar: Hyperfine, Inc. grew EPS 23. 2% year-over-year, compared to 21. 8% for NovoCure Limited. Over a 3-year CAGR, HYPR leads at 25. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — HYPR or NVCR?
NovoCure Limited (NVCR) is the more profitable company, earning -20.
8% net margin versus -262. 3% for Hyperfine, Inc. — meaning it keeps -20. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVCR leads at -23. 5% versus -273. 4% for HYPR. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — HYPR or NVCR?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is HYPR or NVCR better for a retirement portfolio?
For long-horizon retirement investors, NovoCure Limited (NVCR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding.
Hyperfine, Inc. (HYPR) carries a higher beta of 2. 63 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NVCR: +30. 3%, HYPR: -83. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between HYPR and NVCR?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
Revenue Growth>
%
(HYPR: 128.0% · NVCR: 12.3%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.